Dendrimer-Antibody Conjugation Service

Antibodies conjugated to dendrimers can bind to cells expressing antigens with the same affinity as free antibodies. With advanced facilities and experienced scientists, CD BioSciences provides high quality dendrimer-antibody conjugation service.

Introduction into Monoclonal Antibody Drugs

Antibodies are secreted by B-lymphocyte transformed plasma cells, and each B-lymphocyte cell line can only produce one antibody specific to one specific antigenic determinant cluster. Such antibodies produced from a single cell line are called monoclonal antibodies (mAb). It seems that site-specific delivery based on antigen recognition by antibody that overexpressed in tumor cells in comparison to normal cells is essential. Monoclonal antibodies are effective ligands against cancers that overexpress specific antigens. Poor solubility and low binding affinity are major problems with other immunotherapies. Monoclonal antibody therapy, an immunotherapy that uses mAb that bind specifically to certain cells or proteins, not only improves the poor solubility and low affinity problems of other immunotherapies, but also allows the autoimmune system to fight the disease.

Dendrimer-Antibody Conjugation for Cancer Treatment

In contrast to conventional linear polymers, highly branched dendrimers are widely used in biological applications due to their versatility, shape, and defined size, for example, as imaging agents for diagnostics, carriers of genes, drugs, and proteins. Dendrimers are precisely controlled structures that are globular in shape with low poly dispersity. The dendrimer structure is divided into three main parts: the core or nucleus; the inner layer consisting of repeating molecular units called dendrites; and the surface terminal groups. Bioactive molecules can be delivered by dendrimers through internal loading and surface binding. Compared to liposomes, dendrimers have a high drug loading capacity, as demonstrated by the fact that they can be prepared in different sizes and can also be modified by surface-carrying ligands, as well as being biodegradable.

One of the main applications of dendrimers in the biological field is related to cancer therapy, where when they are linked to targeting ligands, bioactive compounds can be specifically delivered to the cancer tissue, reducing off-target effects. Decorating dendrimers with specific ligands or antibodies has been considered as a promising strategy to enable the recognition of target molecules expressed in the tumor microenvironment. Monoclonal antibodies have been identified as useful ligands against cancer cells expressing specific antigens. When monoclonal antibodies are conjugated to dendrimers, not only do the antibodies have the same affinity as free antibodies and are able to bind to cells expressing the antigen, but they also overcome the problems of decreased immune activity and poor solubility that exist with other immunotherapies.

Dendrimer conjugated with FIt-1 antibody can be used for the treatment of pancreatic cancer. (Öztürk K,et al., 2017)

Our Services

As a fast growing and leading global provider of scientific research services and solutions, CD BioSciences has grown to become one of the largest independent biotechnology companies in the world and is connected to millions of researchers and partners worldwide. CD BioSciences leverages its expertise and experience in organic chemistry to provide you with dendrimer-antibody conjugation service. We are committed to meeting all your detailed requirements and guarantee that all deliverables are subjected to rigorous quality testing.

Applications

CD BioSciences can customize dendrimer-antibody conjugation solutions to promote the development of cancer drugs with the power of dendrimer modification.

Service Process

CD BioSciences is committed to helping our customers meet the growing and evolving demand for dendrimer products. We offer a wide range of services related to dendrimers and ensure quality and reliability of results as well as on-time delivery. If you are interested in our services or have any additional questions, please feel free to contact us, we are happy to hear from you and look forward to working with you.

Reference

1. Öztürk K.; et al. Effective targeting of gemcitabine to pancreatic cancer through PEG-cored Flt-1 antibody-conjugated dendrimers. Int J Pharm. 2017, 517: 157-167.